1. Home
  2. MAZE vs ALT Comparison

MAZE vs ALT Comparison

Compare MAZE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAZE
  • ALT
  • Stock Information
  • Founded
  • MAZE 2018
  • ALT 1997
  • Country
  • MAZE United States
  • ALT United States
  • Employees
  • MAZE N/A
  • ALT N/A
  • Industry
  • MAZE
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MAZE
  • ALT Health Care
  • Exchange
  • MAZE NYSE
  • ALT Nasdaq
  • Market Cap
  • MAZE 523.1M
  • ALT 472.3M
  • IPO Year
  • MAZE 2025
  • ALT N/A
  • Fundamental
  • Price
  • MAZE $11.01
  • ALT $5.00
  • Analyst Decision
  • MAZE Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • MAZE 3
  • ALT 8
  • Target Price
  • MAZE $25.67
  • ALT $21.00
  • AVG Volume (30 Days)
  • MAZE 266.1K
  • ALT 3.0M
  • Earning Date
  • MAZE 01-01-0001
  • ALT 05-08-2025
  • Dividend Yield
  • MAZE N/A
  • ALT N/A
  • EPS Growth
  • MAZE N/A
  • ALT N/A
  • EPS
  • MAZE 1.25
  • ALT N/A
  • Revenue
  • MAZE $167,500,000.00
  • ALT $20,000.00
  • Revenue This Year
  • MAZE N/A
  • ALT N/A
  • Revenue Next Year
  • MAZE N/A
  • ALT N/A
  • P/E Ratio
  • MAZE $8.81
  • ALT N/A
  • Revenue Growth
  • MAZE N/A
  • ALT N/A
  • 52 Week Low
  • MAZE $9.88
  • ALT $4.78
  • 52 Week High
  • MAZE $17.00
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • MAZE N/A
  • ALT 35.19
  • Support Level
  • MAZE N/A
  • ALT $5.60
  • Resistance Level
  • MAZE N/A
  • ALT $6.16
  • Average True Range (ATR)
  • MAZE 0.00
  • ALT 0.35
  • MACD
  • MAZE 0.00
  • ALT -0.02
  • Stochastic Oscillator
  • MAZE 0.00
  • ALT 15.94

About MAZE MAZE THERAPEUTICS INC

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: